Objectives: This study sought to expand knowledge on the molecular mechanisms of mutational resistance to trimethoprim in Staphylococcus aureus, and the fitness costs associated with resistance.
Introduction
The diaminopyrimidine antimicrobial trimethoprim ( Figure 1 ) demonstrates broad-spectrum antibacterial activity, which encompasses the human pathogen Staphylococcus aureus. 1 -3 Due to its excellent safety profile, suitability for oral administration and relatively low cost, trimethoprim has been extensively used in clinical practice for treating bacterial infections. 2, 4 Trimethoprim exerts its antibacterial effect through competitive inhibition of dihydrofolate reductase (DHFR), 5 -7 a key enzyme in the folate biosynthesis pathway. As a consequence, intracellular levels of reduced folates become depleted, leading to inhibition of bacterial growth. 7, 8 Trimethoprim exhibits synergistic action with sulphonamides, since the latter also target folate biosynthesis. 7 This synergism has been exploited in the widely used drug combination co-trimoxazole, comprising trimethoprim and sulfamethoxazole, which exhibits good activity against both methicillin-sensitive S. aureus and methicillinresistant S. aureus (MRSA). 3, 7, 9, 10 Furthermore, co-trimoxazole has recently been recommended for the treatment of community-associated MRSA (CA-MRSA) infections, since the causative strains in these infections are typically co-trimoxazolesusceptible. 11, 12 Two distinct mechanisms of trimethoprim resistance have been described in staphylococci: (i) point mutations in the chromosomal dfrA gene, and (ii) horizontal acquisition of resistance determinants, typically plasmid-borne, that encode drug-resistant variants of DHFR (types S1, S2 and S3). 1, 10, 13 Mutation of endogenous DHFR in S. aureus generally confers low-to moderate-level resistance, whereas expression of horizontally acquired DHFR confers high-level resistance.
13 DHFR mutation appears to be the predominant mechanism of trimethoprim resistance in clinical isolates of S. aureus, and is apparently selected even when trimethoprim is used in combination with sulfamethoxazole. 13 However, little is known about the emergence, maintenance and genetic basis of chromosomal resistance to trimethoprim in this pathogen. A greater understanding of these phenomena would be of value, particularly as trimethoprim, in the form of co-trimoxazole, is likely to be used more frequently in the future following recommendations that co-trimoxazole has a role in the management of CA-MRSA infections.
11 Consequently, we have selected trimethoprimresistant mutants of S. aureus in vitro and examined their genetic and physiological characteristics. In addition, we have used in silico modelling techniques to explore the effects of DHFR mutations on enzyme -dihydrofolate/trimethoprim interactions at the structural level.
Materials and methods

Bacterial strains, growth conditions, antimicrobial agents and reagents
Unless stated otherwise, experiments were performed using S. aureus SH1000.
14 Bacteria were cultured with aeration at 378C in Iso-Sensitest broth (ISB) or Iso-Sensitest agar (ISA) (Oxoid, Basingstoke, UK). All antimicrobial agents and laboratory reagents were purchased from Sigma-Aldrich (Poole, UK).
Antibiotic susceptibility testing
Minimum inhibitory concentrations (MICs) were determined by the agar dilution method, 15 using inocula of 10 4 cfu/spot. The MIC was defined as the lowest concentration of antibiotic preventing visible bacterial growth following incubation for 18 h at 378C.
Selection of antibiotic-resistant mutants and determination of mutation frequencies to resistance
Trimethoprim-resistant mutants were recovered by plating aliquots of overnight bacterial cultures onto ISA containing trimethoprim at concentrations above the MIC. Mutation frequency determinations were performed using three independent cultures, each sampled in triplicate, and the results expressed as the number of antibiotic-resistant mutants recovered as a fraction of the viable count. 16 Where appropriate, bacterial cultures were concentrated by centrifugation to recover mutants arising with low frequency.
Genetic characterization of trimethoprim-resistant mutants
To identify trimethoprim resistance mutations, the dfrA gene was PCR-amplified from resistant mutants using oligonucleotide primers dfrU (5 0 -CTAAGTATTCTTTAGATAAATCGGATGTTG) and dfrL (5 0 -GTTTTGAAAATCAATTACCTTGGCACCTAC), under standard cycling conditions. 17 Amplicons were purified using the QIAquick PCR purification kit (Qiagen, Crawley, UK) and sequenced by Cogenics (Takeley, Essex, UK).
To confirm the role of the novel DHFR mutations L 41 F and F 99 S in trimethoprim resistance, the dfrA gene was PCR-amplified under standard cycling conditions from trimethoprim-resistant strains encoding DHFR L41F and DHFR F99S , and from SH1000 and a strain encoding DHFR F99Y (as negative and positive controls, respectively), using oligonucleotide primers dfrMutU (5 0 -GGAAA GGATCCACTATGAATCACATCCAGC and dfrMutL (5 0 -CTG GGATCCTAATCTGTTTTGTCATGGTCG) (engineered restriction sites shown underlined). PCR amplicons were ligated into BamHIdigested pCU1 to generate the constructs pCU1:DHFR wt (wild-type DHFR), pCU1:DHFR 99Y , pCU1:DHFR 41F and pCU1:DHFR 99S . Constructs were propagated in Escherichia coli, recovered using the Wizard Plus SV Mini Prep kit (Promega, Southampton, UK) and subjected to DNA sequencing to verify that no additional mutations had been introduced into dfrA sequences during PCR amplification. Constructs were subsequently introduced into S. aureus RN4220 by electroporation, 18 and trimethoprim susceptibilities determined for the transformants.
Determination of competitive fitness
Fitness costs associated with trimethoprim resistance mutations were determined by pair-wise competition of the resistant mutant with the drug-susceptible progenitor strain (SH1000), essentially as described previously. 19 Briefly, ISB was inoculated with a mixture of overnight cultures of SH1000 and a trimethoprim-resistant mutant in a 10:1 ratio. Dilutions of the mixed cultures were plated onto both non-selective ISA and selective ISA containing trimethoprim at time 0, and after 24 h incubation at 378C. Colony counts on selective agar were adjusted to take account of spontaneous resistance to trimethoprim arising in SH1000 during the course of the experiment, as gauged by parallel experiments with SH1000 monocultures. Relative competitive fitness (W) was calculated according to the equation
and N S (t) represent viable counts of the resistant strain and SH1000, respectively, at time t (either 0 or 24 h). 20 Fitness determinations were conducted at least in triplicate.
Molecular modelling
Molecular models of S. aureus DHFR (wild-type and mutated trimethoprim-resistant forms) were constructed using the SWISS-MODEL workspace 21 -23 in conjunction with UniProtKB/ Swiss-Prot entry P0A017 of S. aureus DHFR. Trimethoprim resistance mutations were introduced into the workspace input to generate mutated DHFR structures. Trimethoprim, reduced nicotinamide adenine dinucleotide phosphate (NADPH) and dihydrofolate were mapped onto the enzyme models by overlapping coordinates with E. coli DHFR enzymes in which these ligands were complexed (1DG5.pdb and 1RX2.pdb) using MacroModel. 24 The resulting Trimethoprim resistance in S. aureus structure files were subjected to full global energy minimization using the Merck Molecular Force Field (MMFF) within MacroModel. An additional force field was used to simulate a solvent dielectric equivalent to water.
Results and discussion
Isolation and susceptibility testing of trimethoprim-resistant derivates of S. aureus SH1000 Spontaneous trimethoprim-resistant mutants were recovered from several independent cultures of S. aureus SH1000. Since we observed a strong inoculum effect upon trimethoprim susceptibility, as described previously for other bacterial species, 25 high concentrations of trimethoprim were employed to prevent 'break-through' growth of trimethoprim-susceptible strains on the selective agar. Mutants arose at frequencies of 1.18+1.11Â10 29 , 2.29+2.52Â10 210 and 1.06+0.27Â10 210 on media containing 16, 32 and 64 mg/L trimethoprim, respectively. These mutation frequencies are relatively low when compared with mutation frequencies for resistance to other classes of antimicrobials. For example, mutation frequencies for single-step resistance to norfloxacin, novobiocin, rifampicin, fusidic acid and mupirocin in S. aureus are between 10 27 and 10
28
. 16, 26 Nonetheless, the frequencies of trimethoprim resistance determined in this work are consistent with single mutational events. 26 Trimethoprim susceptibility testing of the recovered mutants established that they were 4-to 16-fold less susceptible to trimethoprim than the progenitor strain, SH1000. The selection, on plates containing trimethoprim up to 64Â MIC, of mutants exhibiting only up to 16-fold reductions in susceptibility to trimethoprim is almost certainly a consequence of the inoculum effect mentioned earlier, with the high inocula used (.10 10 cfu) reducing the effective trimethoprim concentration during selective platings.
Characterization of trimethoprim resistance genotypes
Twenty-two strains exhibiting a range of trimethoprim susceptibilities were chosen for further characterization by PCR amplification and DNA sequencing of dfrA. All strains carried point mutations encoding single amino acid substitutions in DHFR, and most (19/22) had DHFR mutations that have been described previously among clinical isolates of S. aureus (F 99 Y or H 150 R). 13 Two novel DHFR mutations were identified: L 41 F and F 99 S. DHFR substitutions L 41 F, F 99 S, H 150 R and F 99 Y conferred 4-, 4-, 8-and 16-fold increases in resistance to trimethoprim, respectively, relative to the parental SH1000 strain (Table 1) . Consistent with its high prevalence among trimethoprimresistant strains in the clinic, 13 the active site mutation F 99 Y was detected in over half of the resistant mutants characterized.
Confirmation of the role of novel DHFR mutations F 99 S and L 41 F in resistance to trimethoprim
The effect of DHFR mutations L 41 F and F 99 S on trimethoprim susceptibility was investigated by ectopic expression in RN4220 of the dfrA genes encoding DHFR L41F and DHFR F99S . Transformation of RN4220 with plasmid pCU1:DHFR wt , which carries the wild-type dfrA sequence from SH1000, conferred a 16-fold decrease in susceptibility to trimethoprim compared with RN4220 and RN4220(pCU1), raising the trimethoprim MIC from 1 to 16 mg/L. This increase was almost certainly the result of increased DHFR expression due to elevated gene dosage. Ectopic expression of the known dfrA resistance allele encoding DHFR F99Y gave rise to a trimethoprim MIC of 512 mg/L. This 32-fold reduction in trimethoprim susceptibility over RN4220(pCU1:DHFR wt ) is similar to the 16-fold reduction in susceptibility over SH1000 that this resistance allele confers when present on the chromosome (Table 1) , and provides confirmation for ectopic expression as a viable approach to assess the role of DHFR mutations in trimethoprim resistance. Transformation of RN4220 with plasmid pCU1:DHFR 41F or pCU1:DHFR 99S gave rise to trimethoprim MICs of 128 mg/L, 8-fold higher than that conferred by ectopic expression of the wild-type enzyme, confirming that DHFR mutations L 41 F and F 99 S confer reduced susceptibility to trimethoprim in S. aureus.
In vitro fitness of trimethoprim-resistant mutants of S. aureus
The in vitro fitness of four trimethoprim-resistant mutants of S. aureus SH1000, representing each of the resistance genotypes identified, was determined in pair-wise competition assays. Resistance-determining dfrA mutations were not associated with fitness costs in vitro (Table 1) . For the DHFR F 99 Y substitution, a lack of fitness cost is consistent with an earlier study in which the kinetic properties of wild-type and trimethoprim-resistant (F 99 Y) S. aureus DHFRs were compared. 13 In contrast to the large difference in the activities of trimethoprim against the wild-type and the mutant enzymes in vitro, only modest changes were observed for the other kinetic parameters, 13 implying that trimethoprim resistance is gained without significant cost to DHFR function. Furthermore, the absence of fitness costs associated with the DHFR F 99 Y mutation is consistent with the high prevalence of this mutation among intermediate-level trimethoprim-resistant mutants of S. aureus in the clinic. 13 The other DHFR mutations may also have a no-cost nature in vivo, might therefore not be disadvantaged relative to trimethoprim-susceptible strains and could persist among natural populations of staphylococci. 27 Relationship of resistance and fitness to molecular structure: application of molecular modelling Molecular models of S. aureus DHFR (wild-type and mutated trimethoprim-resistant forms) were constructed in silico (Figures 2 and 3 ). These models were used to quantify the effect of mutations on the binding energy of trimethoprim, and to establish the precise interactions responsible for any changes in binding energy. In general, there appears to be a broad correlation between the calculated loss of trimethoprim -DHFR binding energy and the measured trimethoprim MICs for resistant strains ( Table 1 ). The effects of trimethoprim resistance mutations on the binding of dihydrofolate to the enzyme were also examined to rationalize observed in vitro fitness data for trimethoprim-resistant mutants. The observed absence of fitness costs is supported by the similar values for the binding energy of dihydrofolate within these complexes (Table 1) . As mentioned, the mutant enzymes exhibit lower trimethoprim -protein binding energies than those calculated for the wild-type (Table 1) . Detailed examination of the molecular models (Figures 2 and 3 ) reveals some of the structural factors that may affect the binding of trimethoprim to these mutant enzymes.
Wild-type. In wild-type DHFR, trimethoprim makes four hydrogen bonds; two from the 2-amino group of trimethoprim to the side-chain hydroxyl of T 112 and to the side-chain carbonyl of D 28 . The 4-amino group also makes two hydrogen bonds to the mainchain carbonyl of L 6 and to the main-chain carbonyl of F 93 . When NADPH is present, the hydrogen bond with F 93 is replaced by a stronger hydrogen bond with the amide carbonyl of NADPH.
L 41 F. L 41 is located on the edge of the trimethoprim binding pocket but is also in close proximity to F 93 . Substitution of L 41 results in a large movement of F 93 to partially pi-stack with mutated F 41 , and trimethoprim is forced to move in order to accommodate the movement of F 93 . This causes a severe steric clash between the trimethoxyl ring of trimethoprim and L 21 , making trimethoprim binding unfavourable. This is exacerbated by the inability of the 4-amino group of trimethoprim to maintain a hydrogen bond with F 93 or NADPH.
F 99 S. Mutation from a large aromatic side chain to a small polar side chain alters the hydrophobicity of the NADPH binding pocket. This causes the co-factor to lose its partial pi-stacking with F 99 , and to move out of the pocket since it can no longer maintain a hydrophobic interaction. This movement causes a steric clash between trimethoprim and NADPH, forcing trimethoprim to shift. This results in loss of a hydrogen bond between the 4-amino group of trimethoprim and the backbone carbonyl of L 6 .
F 99 Y. Consistent with previous studies involving molecular modelling of DHFR mutation F 99 Y, 13 our model suggests that the main factor contributing to trimethoprim resistance is the loss of the hydrogen bond between L 6 and the 4-amino group of trimethoprim. However, in contrast to the earlier study, we observe that the loss of this hydrogen bond is due to a widening of the trimethoprim binding pocket. This widening appears to result from formation of a hydrogen bond between the hydroxyl of Y 99 and the amide carbonyl of NADPH, which ultimately results in a closer proximity of NADPH to the protein in the region of Y 99 . As the volume of the trimethoprim binding pocket is slightly increased, trimethoprim is consequently unable to maintain a hydrogen bond with L 6 .
H 150 R. H 150 makes two hydrogen bonds with N 27 and I 148 . Mutation of H 150 to R 150 causes these original hydrogen bonds to be broken and new hydrogen bonds to be formed between the side-chain carbonyls of D 28 /N 146 and two N-H units within the guanidinium moiety of R 150 . The movement of residue 28, caused by the rearrangement in the hydrogen bonding network, results in the loss of a hydrogen bond to the 2-amino group of trimethoprim. The reordering of the hydrogen bonding network in this region, along with the movement of L 29 impinging on the trimethoprim binding region, would appear to be responsible for the reduced ability of trimethoprim to bind to the enzyme.
Conclusions
These studies have identified two novel trimethoprim resistance mutations in S. aureus, and provide plausible structural explanations for reductions in trimethoprim susceptibility conferred by resistance mutations.
Mutation frequencies to trimethoprim resistance were relatively low. These findings are encouraging and suggest that, should trimethoprim (in the form of co-trimoxazole) become more widely used for the management of staphylococcal infections, the emergence of trimethoprim resistance in vivo may be relatively infrequent. However, fitness studies predict that when trimethoprim-resistant strains emerge, their persistence may not be restricted by a fitness cost. 
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